Ninepoint Partners LP Makes New Investment in Edwards Lifesciences Corporation $EW

Ninepoint Partners LP purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 19,763 shares of the medical research company’s stock, valued at approximately $1,788,000.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. bought a new stake in Edwards Lifesciences during the second quarter worth approximately $5,318,092,000. State Street Corp raised its position in shares of Edwards Lifesciences by 1.5% in the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP lifted its stake in shares of Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after buying an additional 989,533 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $1,274,082,000. Finally, Norges Bank bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $803,686,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $90.02 on Friday. The company’s fifty day moving average is $89.12 and its two-hundred day moving average is $84.63. The firm has a market capitalization of $51.83 billion, a price-to-earnings ratio of 51.74, a P/E/G ratio of 2.32 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the company earned $0.67 earnings per share. The firm’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently commented on the stock. UBS Group started coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price on the stock. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, BTIG Research raised their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.